nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—ORM1—Vandetanib—thyroid cancer	0.372	0.477	CbGbCtD
Mirabegron—ALB—Vandetanib—thyroid cancer	0.156	0.201	CbGbCtD
Mirabegron—ABCB1—Sorafenib—thyroid cancer	0.0493	0.0633	CbGbCtD
Mirabegron—CYP3A4—Vandetanib—thyroid cancer	0.049	0.063	CbGbCtD
Mirabegron—CYP2D6—Sorafenib—thyroid cancer	0.0465	0.0597	CbGbCtD
Mirabegron—ABCB1—Doxorubicin—thyroid cancer	0.0299	0.0384	CbGbCtD
Mirabegron—CYP3A4—Sorafenib—thyroid cancer	0.0296	0.0379	CbGbCtD
Mirabegron—CYP2D6—Doxorubicin—thyroid cancer	0.0282	0.0362	CbGbCtD
Mirabegron—CYP3A4—Doxorubicin—thyroid cancer	0.0179	0.023	CbGbCtD
Mirabegron—Leukocytoclastic vasculitis—Sorafenib—thyroid cancer	0.00593	0.0268	CcSEcCtD
Mirabegron—Glaucoma—Vandetanib—thyroid cancer	0.00573	0.0259	CcSEcCtD
Mirabegron—Nephrolithiasis—Vandetanib—thyroid cancer	0.00536	0.0242	CcSEcCtD
Mirabegron—Cystitis noninfective—Vandetanib—thyroid cancer	0.00421	0.019	CcSEcCtD
Mirabegron—Cystitis—Vandetanib—thyroid cancer	0.00416	0.0188	CcSEcCtD
Mirabegron—Dry eye—Vandetanib—thyroid cancer	0.00398	0.018	CcSEcCtD
Mirabegron—Neoplasm—Vandetanib—thyroid cancer	0.0039	0.0176	CcSEcCtD
Mirabegron—Bladder pain—Vandetanib—thyroid cancer	0.0039	0.0176	CcSEcCtD
Mirabegron—Atrial fibrillation—Vandetanib—thyroid cancer	0.0033	0.0149	CcSEcCtD
Mirabegron—Blood pressure increased—Sorafenib—thyroid cancer	0.00291	0.0131	CcSEcCtD
Mirabegron—Rash papular—Epirubicin—thyroid cancer	0.00289	0.013	CcSEcCtD
Mirabegron—Nasopharyngitis—Vandetanib—thyroid cancer	0.0028	0.0126	CcSEcCtD
Mirabegron—Gastritis—Vandetanib—thyroid cancer	0.00277	0.0125	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.00276	0.0125	CcSEcCtD
Mirabegron—Influenza—Vandetanib—thyroid cancer	0.0027	0.0122	CcSEcCtD
Mirabegron—Rash papular—Doxorubicin—thyroid cancer	0.00267	0.0121	CcSEcCtD
Mirabegron—Neoplasm—Sorafenib—thyroid cancer	0.00263	0.0119	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00251	0.0114	CcSEcCtD
Mirabegron—Infestation NOS—Vandetanib—thyroid cancer	0.00241	0.0109	CcSEcCtD
Mirabegron—Infestation—Vandetanib—thyroid cancer	0.00241	0.0109	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00239	0.0108	CcSEcCtD
Mirabegron—Urinary tract infection—Vandetanib—thyroid cancer	0.00234	0.0106	CcSEcCtD
Mirabegron—Sinusitis—Vandetanib—thyroid cancer	0.00226	0.0102	CcSEcCtD
Mirabegron—Urinary tract disorder—Vandetanib—thyroid cancer	0.00214	0.00966	CcSEcCtD
Mirabegron—Urethral disorder—Vandetanib—thyroid cancer	0.00212	0.00959	CcSEcCtD
Mirabegron—Lactic dehydrogenase activity increased—Epirubicin—thyroid cancer	0.0021	0.00949	CcSEcCtD
Mirabegron—Erythema multiforme—Vandetanib—thyroid cancer	0.00205	0.00925	CcSEcCtD
Mirabegron—Eye disorder—Vandetanib—thyroid cancer	0.00202	0.00914	CcSEcCtD
Mirabegron—Cardiac disorder—Vandetanib—thyroid cancer	0.00201	0.00908	CcSEcCtD
Mirabegron—Lactic dehydrogenase activity increased—Doxorubicin—thyroid cancer	0.00194	0.00878	CcSEcCtD
Mirabegron—Breast disorder—Sorafenib—thyroid cancer	0.00191	0.00862	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.0019	0.00859	CcSEcCtD
Mirabegron—Nasopharyngitis—Sorafenib—thyroid cancer	0.00189	0.00853	CcSEcCtD
Mirabegron—Gastritis—Sorafenib—thyroid cancer	0.00187	0.00844	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00186	0.00842	CcSEcCtD
Mirabegron—Blood lactate dehydrogenase increased—Epirubicin—thyroid cancer	0.00185	0.00836	CcSEcCtD
Mirabegron—Vision blurred—Vandetanib—thyroid cancer	0.00178	0.00803	CcSEcCtD
Mirabegron—Blood lactate dehydrogenase increased—Doxorubicin—thyroid cancer	0.00171	0.00773	CcSEcCtD
Mirabegron—Hypertension—Vandetanib—thyroid cancer	0.00163	0.00735	CcSEcCtD
Mirabegron—Infestation NOS—Sorafenib—thyroid cancer	0.00163	0.00735	CcSEcCtD
Mirabegron—Infestation—Sorafenib—thyroid cancer	0.00163	0.00735	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00161	0.00729	CcSEcCtD
Mirabegron—Arthralgia—Vandetanib—thyroid cancer	0.0016	0.00725	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00159	0.0072	CcSEcCtD
Mirabegron—Dry mouth—Vandetanib—thyroid cancer	0.00157	0.00709	CcSEcCtD
Mirabegron—Infection—Vandetanib—thyroid cancer	0.00153	0.00691	CcSEcCtD
Mirabegron—Skin disorder—Vandetanib—thyroid cancer	0.00149	0.00675	CcSEcCtD
Mirabegron—Urinary tract disorder—Sorafenib—thyroid cancer	0.00144	0.00652	CcSEcCtD
Mirabegron—Connective tissue disorder—Sorafenib—thyroid cancer	0.00144	0.00649	CcSEcCtD
Mirabegron—Urethral disorder—Sorafenib—thyroid cancer	0.00143	0.00647	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.0014	0.00633	CcSEcCtD
Mirabegron—Erythema multiforme—Sorafenib—thyroid cancer	0.00138	0.00624	CcSEcCtD
Mirabegron—Cardiac disorder—Sorafenib—thyroid cancer	0.00136	0.00613	CcSEcCtD
Mirabegron—Dyspepsia—Vandetanib—thyroid cancer	0.00135	0.00612	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00133	0.006	CcSEcCtD
Mirabegron—Fatigue—Vandetanib—thyroid cancer	0.00133	0.00599	CcSEcCtD
Mirabegron—Constipation—Vandetanib—thyroid cancer	0.00132	0.00595	CcSEcCtD
Mirabegron—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00126	0.00568	CcSEcCtD
Mirabegron—Abdominal pain—Vandetanib—thyroid cancer	0.00122	0.0055	CcSEcCtD
Mirabegron—Asthenia—Vandetanib—thyroid cancer	0.0011	0.00499	CcSEcCtD
Mirabegron—Hypertension—Sorafenib—thyroid cancer	0.0011	0.00496	CcSEcCtD
Mirabegron—Pruritus—Vandetanib—thyroid cancer	0.00109	0.00492	CcSEcCtD
Mirabegron—Arthralgia—Sorafenib—thyroid cancer	0.00108	0.00489	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00107	0.00486	CcSEcCtD
Mirabegron—Dry mouth—Sorafenib—thyroid cancer	0.00106	0.00478	CcSEcCtD
Mirabegron—Diarrhoea—Vandetanib—thyroid cancer	0.00105	0.00476	CcSEcCtD
Mirabegron—Cystitis noninfective—Epirubicin—thyroid cancer	0.00105	0.00475	CcSEcCtD
Mirabegron—Cystitis—Epirubicin—thyroid cancer	0.00104	0.00469	CcSEcCtD
Mirabegron—Infection—Sorafenib—thyroid cancer	0.00103	0.00466	CcSEcCtD
Mirabegron—Dizziness—Vandetanib—thyroid cancer	0.00102	0.0046	CcSEcCtD
Mirabegron—Vaginal infection—Epirubicin—thyroid cancer	0.00101	0.00459	CcSEcCtD
Mirabegron—Skin disorder—Sorafenib—thyroid cancer	0.00101	0.00456	CcSEcCtD
Mirabegron—Dry eye—Epirubicin—thyroid cancer	0.000993	0.00449	CcSEcCtD
Mirabegron—Bladder pain—Epirubicin—thyroid cancer	0.000972	0.00439	CcSEcCtD
Mirabegron—Neoplasm—Epirubicin—thyroid cancer	0.000972	0.00439	CcSEcCtD
Mirabegron—Cystitis noninfective—Doxorubicin—thyroid cancer	0.000971	0.00439	CcSEcCtD
Mirabegron—Rash—Vandetanib—thyroid cancer	0.00097	0.00438	CcSEcCtD
Mirabegron—Dermatitis—Vandetanib—thyroid cancer	0.000969	0.00438	CcSEcCtD
Mirabegron—Headache—Vandetanib—thyroid cancer	0.000964	0.00436	CcSEcCtD
Mirabegron—Cystitis—Doxorubicin—thyroid cancer	0.00096	0.00434	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000945	0.00427	CcSEcCtD
Mirabegron—Vaginal infection—Doxorubicin—thyroid cancer	0.000939	0.00424	CcSEcCtD
Mirabegron—Dry eye—Doxorubicin—thyroid cancer	0.000919	0.00415	CcSEcCtD
Mirabegron—Nausea—Vandetanib—thyroid cancer	0.000914	0.00413	CcSEcCtD
Mirabegron—Dyspepsia—Sorafenib—thyroid cancer	0.000913	0.00413	CcSEcCtD
Mirabegron—Neoplasm—Doxorubicin—thyroid cancer	0.000899	0.00406	CcSEcCtD
Mirabegron—Bladder pain—Doxorubicin—thyroid cancer	0.000899	0.00406	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000896	0.00405	CcSEcCtD
Mirabegron—Fatigue—Sorafenib—thyroid cancer	0.000895	0.00404	CcSEcCtD
Mirabegron—Constipation—Sorafenib—thyroid cancer	0.000887	0.00401	CcSEcCtD
Mirabegron—Vascular purpura—Epirubicin—thyroid cancer	0.000872	0.00394	CcSEcCtD
Mirabegron—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000848	0.00383	CcSEcCtD
Mirabegron—Urticaria—Sorafenib—thyroid cancer	0.000824	0.00373	CcSEcCtD
Mirabegron—Abdominal pain—Sorafenib—thyroid cancer	0.00082	0.00371	CcSEcCtD
Mirabegron—Purpura—Epirubicin—thyroid cancer	0.000809	0.00366	CcSEcCtD
Mirabegron—Vascular purpura—Doxorubicin—thyroid cancer	0.000807	0.00365	CcSEcCtD
Mirabegron—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000796	0.0036	CcSEcCtD
Mirabegron—Osteoarthritis—Epirubicin—thyroid cancer	0.00078	0.00353	CcSEcCtD
Mirabegron—Purpura—Doxorubicin—thyroid cancer	0.000749	0.00339	CcSEcCtD
Mirabegron—Asthenia—Sorafenib—thyroid cancer	0.000744	0.00336	CcSEcCtD
Mirabegron—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000737	0.00333	CcSEcCtD
Mirabegron—Pruritus—Sorafenib—thyroid cancer	0.000734	0.00332	CcSEcCtD
Mirabegron—Osteoarthritis—Doxorubicin—thyroid cancer	0.000722	0.00326	CcSEcCtD
Mirabegron—Diarrhoea—Sorafenib—thyroid cancer	0.00071	0.00321	CcSEcCtD
Mirabegron—Breast disorder—Epirubicin—thyroid cancer	0.000705	0.00319	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000703	0.00318	CcSEcCtD
Mirabegron—Nasopharyngitis—Epirubicin—thyroid cancer	0.000698	0.00315	CcSEcCtD
Mirabegron—Gastritis—Epirubicin—thyroid cancer	0.00069	0.00312	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000688	0.00311	CcSEcCtD
Mirabegron—Dizziness—Sorafenib—thyroid cancer	0.000686	0.0031	CcSEcCtD
Mirabegron—Abdominal distension—Epirubicin—thyroid cancer	0.000679	0.00307	CcSEcCtD
Mirabegron—Influenza—Epirubicin—thyroid cancer	0.000674	0.00305	CcSEcCtD
Mirabegron—Rash—Sorafenib—thyroid cancer	0.000654	0.00296	CcSEcCtD
Mirabegron—Dermatitis—Sorafenib—thyroid cancer	0.000654	0.00295	CcSEcCtD
Mirabegron—Breast disorder—Doxorubicin—thyroid cancer	0.000652	0.00295	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00065	0.00294	CcSEcCtD
Mirabegron—Headache—Sorafenib—thyroid cancer	0.00065	0.00294	CcSEcCtD
Mirabegron—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000646	0.00292	CcSEcCtD
Mirabegron—Gastritis—Doxorubicin—thyroid cancer	0.000639	0.00289	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000637	0.00288	CcSEcCtD
Mirabegron—Abdominal distension—Doxorubicin—thyroid cancer	0.000628	0.00284	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000627	0.00283	CcSEcCtD
Mirabegron—Influenza—Doxorubicin—thyroid cancer	0.000624	0.00282	CcSEcCtD
Mirabegron—Nausea—Sorafenib—thyroid cancer	0.000616	0.00279	CcSEcCtD
Mirabegron—Infestation NOS—Epirubicin—thyroid cancer	0.000601	0.00272	CcSEcCtD
Mirabegron—Infestation—Epirubicin—thyroid cancer	0.000601	0.00272	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000596	0.00269	CcSEcCtD
Mirabegron—Urinary tract infection—Epirubicin—thyroid cancer	0.000584	0.00264	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00058	0.00262	CcSEcCtD
Mirabegron—Sinusitis—Epirubicin—thyroid cancer	0.000564	0.00255	CcSEcCtD
Mirabegron—Infestation—Doxorubicin—thyroid cancer	0.000556	0.00251	CcSEcCtD
Mirabegron—Infestation NOS—Doxorubicin—thyroid cancer	0.000556	0.00251	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000552	0.00249	CcSEcCtD
Mirabegron—Rhinitis—Epirubicin—thyroid cancer	0.000541	0.00245	CcSEcCtD
Mirabegron—Urinary tract infection—Doxorubicin—thyroid cancer	0.000541	0.00244	CcSEcCtD
Mirabegron—Urinary tract disorder—Epirubicin—thyroid cancer	0.000533	0.00241	CcSEcCtD
Mirabegron—Connective tissue disorder—Epirubicin—thyroid cancer	0.00053	0.0024	CcSEcCtD
Mirabegron—Urethral disorder—Epirubicin—thyroid cancer	0.000529	0.00239	CcSEcCtD
Mirabegron—Sinusitis—Doxorubicin—thyroid cancer	0.000522	0.00236	CcSEcCtD
Mirabegron—Erythema multiforme—Epirubicin—thyroid cancer	0.00051	0.00231	CcSEcCtD
Mirabegron—Eye disorder—Epirubicin—thyroid cancer	0.000504	0.00228	CcSEcCtD
Mirabegron—Cardiac disorder—Epirubicin—thyroid cancer	0.000501	0.00226	CcSEcCtD
Mirabegron—Rhinitis—Doxorubicin—thyroid cancer	0.000501	0.00226	CcSEcCtD
Mirabegron—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000493	0.00223	CcSEcCtD
Mirabegron—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000491	0.00222	CcSEcCtD
Mirabegron—Urethral disorder—Doxorubicin—thyroid cancer	0.00049	0.00221	CcSEcCtD
Mirabegron—Erythema multiforme—Doxorubicin—thyroid cancer	0.000472	0.00213	CcSEcCtD
Mirabegron—Eye disorder—Doxorubicin—thyroid cancer	0.000467	0.00211	CcSEcCtD
Mirabegron—Cardiac disorder—Doxorubicin—thyroid cancer	0.000463	0.00209	CcSEcCtD
Mirabegron—Back pain—Epirubicin—thyroid cancer	0.000454	0.00205	CcSEcCtD
Mirabegron—Vision blurred—Epirubicin—thyroid cancer	0.000443	0.002	CcSEcCtD
Mirabegron—Back pain—Doxorubicin—thyroid cancer	0.000421	0.0019	CcSEcCtD
Mirabegron—Palpitations—Epirubicin—thyroid cancer	0.000415	0.00188	CcSEcCtD
Mirabegron—Vision blurred—Doxorubicin—thyroid cancer	0.00041	0.00185	CcSEcCtD
Mirabegron—Hypertension—Epirubicin—thyroid cancer	0.000406	0.00183	CcSEcCtD
Mirabegron—Arthralgia—Epirubicin—thyroid cancer	0.0004	0.00181	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000397	0.0018	CcSEcCtD
Mirabegron—Dry mouth—Epirubicin—thyroid cancer	0.000391	0.00177	CcSEcCtD
Mirabegron—Palpitations—Doxorubicin—thyroid cancer	0.000384	0.00174	CcSEcCtD
Mirabegron—Infection—Epirubicin—thyroid cancer	0.000381	0.00172	CcSEcCtD
Mirabegron—Hypertension—Doxorubicin—thyroid cancer	0.000375	0.0017	CcSEcCtD
Mirabegron—Tachycardia—Epirubicin—thyroid cancer	0.000374	0.00169	CcSEcCtD
Mirabegron—Skin disorder—Epirubicin—thyroid cancer	0.000372	0.00168	CcSEcCtD
Mirabegron—Arthralgia—Doxorubicin—thyroid cancer	0.00037	0.00167	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000368	0.00166	CcSEcCtD
Mirabegron—Dry mouth—Doxorubicin—thyroid cancer	0.000362	0.00164	CcSEcCtD
Mirabegron—Infection—Doxorubicin—thyroid cancer	0.000352	0.00159	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000349	0.00158	CcSEcCtD
Mirabegron—Tachycardia—Doxorubicin—thyroid cancer	0.000346	0.00157	CcSEcCtD
Mirabegron—Skin disorder—Doxorubicin—thyroid cancer	0.000345	0.00156	CcSEcCtD
Mirabegron—Dyspepsia—Epirubicin—thyroid cancer	0.000338	0.00153	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000331	0.0015	CcSEcCtD
Mirabegron—Fatigue—Epirubicin—thyroid cancer	0.000331	0.00149	CcSEcCtD
Mirabegron—Constipation—Epirubicin—thyroid cancer	0.000328	0.00148	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000323	0.00146	CcSEcCtD
Mirabegron—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000314	0.00142	CcSEcCtD
Mirabegron—Dyspepsia—Doxorubicin—thyroid cancer	0.000312	0.00141	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000306	0.00138	CcSEcCtD
Mirabegron—Fatigue—Doxorubicin—thyroid cancer	0.000306	0.00138	CcSEcCtD
Mirabegron—Urticaria—Epirubicin—thyroid cancer	0.000305	0.00138	CcSEcCtD
Mirabegron—Constipation—Doxorubicin—thyroid cancer	0.000303	0.00137	CcSEcCtD
Mirabegron—Abdominal pain—Epirubicin—thyroid cancer	0.000303	0.00137	CcSEcCtD
Mirabegron—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00029	0.00131	CcSEcCtD
Mirabegron—Urticaria—Doxorubicin—thyroid cancer	0.000282	0.00127	CcSEcCtD
Mirabegron—Abdominal pain—Doxorubicin—thyroid cancer	0.00028	0.00127	CcSEcCtD
Mirabegron—Asthenia—Epirubicin—thyroid cancer	0.000275	0.00124	CcSEcCtD
Mirabegron—Pruritus—Epirubicin—thyroid cancer	0.000271	0.00123	CcSEcCtD
Mirabegron—Diarrhoea—Epirubicin—thyroid cancer	0.000262	0.00119	CcSEcCtD
Mirabegron—Asthenia—Doxorubicin—thyroid cancer	0.000255	0.00115	CcSEcCtD
Mirabegron—Dizziness—Epirubicin—thyroid cancer	0.000254	0.00115	CcSEcCtD
Mirabegron—Pruritus—Doxorubicin—thyroid cancer	0.000251	0.00113	CcSEcCtD
Mirabegron—Diarrhoea—Doxorubicin—thyroid cancer	0.000243	0.0011	CcSEcCtD
Mirabegron—Rash—Epirubicin—thyroid cancer	0.000242	0.00109	CcSEcCtD
Mirabegron—Dermatitis—Epirubicin—thyroid cancer	0.000242	0.00109	CcSEcCtD
Mirabegron—Headache—Epirubicin—thyroid cancer	0.00024	0.00109	CcSEcCtD
Mirabegron—Dizziness—Doxorubicin—thyroid cancer	0.000235	0.00106	CcSEcCtD
Mirabegron—Nausea—Epirubicin—thyroid cancer	0.000228	0.00103	CcSEcCtD
Mirabegron—Rash—Doxorubicin—thyroid cancer	0.000224	0.00101	CcSEcCtD
Mirabegron—Dermatitis—Doxorubicin—thyroid cancer	0.000224	0.00101	CcSEcCtD
Mirabegron—Headache—Doxorubicin—thyroid cancer	0.000222	0.001	CcSEcCtD
Mirabegron—Nausea—Doxorubicin—thyroid cancer	0.000211	0.000953	CcSEcCtD
